AKRO - Akero Therapeutics, Inc. - SEC Form 4 Insider Trading Screener
23 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2020-02-10 | AKRO | Venbio Global Strategic Fund II L.P. | 10% | S - Sale | $27.07 | -10,026 | 3,233,671 | 0% | -$271,399 | |||||
2020-02-06 | AKRO | Venbio Global Strategic Fund II L.P. | 10% | S - Sale | $27.03 | -6,102 | 3,233,697 | 0% | -$164,955 | ||||||
| M | 2020-02-04 | AKRO | Venbio Global Strategic Fund II L.P. | 10% | S - Sale | $25.77 | -82,339 | 3,239,799 | -2% | -$2,121,726 | |||||
| M | 2020-01-16 | AKRO | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $20.87 | -59,532 | 3,092,698 | -2% | -$1,242,403 | |||||
| M | 2020-01-10 | AKRO | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $20.04 | -50,837 | 3,152,230 | -2% | -$1,018,571 | |||||
2020-01-13 | AKRO | Venbio Global Strategic Fund II L.P. | 10% | S - Sale | $20.23 | -494,000 | 3,322,138 | -13% | -$9,993,620 | ||||||
2020-01-08 | AKRO | Venbio Global Strategic Fund II L.P. | 10% | S - Sale | $19.86 | -15,677 | 3,816,138 | 0% | -$311,355 | ||||||
| M | 2020-01-07 | AKRO | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $19.99 | -53,057 | 3,203,067 | -2% | -$1,060,845 | |||||
| M | 2020-01-06 | AKRO | Venbio Global Strategic Fund II L.P. | 10% | S - Sale | $19.86 | -73,221 | 3,831,815 | -2% | -$1,454,530 | |||||
| M | 2020-01-02 | AKRO | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $19.70 | -72,444 | 3,256,124 | -2% | -$1,427,272 | |||||
| M | 2020-01-02 | AKRO | Venbio Global Strategic Fund II L.P. | 10% | S - Sale | $19.71 | -35,498 | 3,905,036 | -1% | -$699,721 | |||||
2019-12-31 | AKRO | Venbio Global Strategic Fund II L.P. | 10% | S - Sale | $23.96 | -14,324 | 3,940,534 | 0% | -$343,259 | ||||||
| AM | 2019-12-27 | AKRO | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $24.20 | -389,382 | 3,656,585 | -10% | -$9,421,175 | |||||
| M | 2019-12-27 | AKRO | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $24.20 | -389,382 | 3,656,585 | -10% | -$9,421,175 | |||||
| M | 2019-12-20 | AKRO | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $21.34 | -49,220 | 4,045,967 | -1% | -$1,050,416 | |||||
| M | 2019-12-17 | AKRO | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $19.56 | -9,671 | 4,095,187 | 0% | -$189,197 | |||||
| D | 2019-06-24 | AKRO | Bitterman Kevin | Dir | P - Purchase | $16.00 | +270,000 | 505,099 | +115% | +$4,320,000 | |||||
| D | 2019-06-24 | AKRO | Atlas Venture Fund Xi, L.P. | 10% | P - Purchase | $16.00 | +270,000 | 505,099 | +115% | +$4,320,000 | |||||
| D | 2019-06-24 | AKRO | Royston Aaron | Dir | P - Purchase | $16.00 | +250,000 | 3,954,858 | +7% | +$4,000,000 | |||||
| D | 2019-06-24 | AKRO | Versant Venture Capital Vi, L.P. | 10% | P - Purchase | $16.00 | +400,000 | 4,104,858 | +11% | +$6,400,000 | |||||
| D | 2019-06-24 | AKRO | Harrison Seth Loring | Dir, 10% | P - Purchase | $16.00 | +900,000 | 5,415,203 | +20% | +$14,400,000 | |||||
| D | 2019-06-24 | AKRO | Apple Tree Partners Iv, L.P. | 10% | P - Purchase | $16.00 | +900,000 | 5,415,203 | +20% | +$14,400,000 | |||||
| D | 2019-06-24 | AKRO | Venbio Global Strategic Fund II L.P. | 10% | P - Purchase | $16.00 | +250,000 | 3,954,858 | +7% | +$4,000,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |